0.39 USD
▲-0.00+3.44%
盘后 0.37 -1.68%
2026-08-03
市值
$48.71M
市盈率
—
EPS
-0.04
股息率
—
52 周区间
0.29 – 3.53
成交量
313.28K
Beta
2.22
目标价
1.50
52W 低 0.2952W 高 3.53
价格走势
公司简介
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase II...